Novartis AG ADR (NVS)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $303.12B
Last updated: Nov 17, 2026 at 11:06 AM ET
Novartis AG ADR (NVS) Government Contracts
Federal agencies obligated $29.09M to Novartis AG ADR over the 12 months through Jul 31, 2026, up 42.0% from the prior 12 months. That is less than 1% of its revenue. Department of Veterans Affairs was the top awarding agency with 85.1% of obligations across 3 agencies.
Federal Obligations
Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated.
- Obligations
- $29.09M
- Change
- +42.0%
- Obligations to revenue
- 0.1%
| Prior 12 months | $20.49M |
|---|---|
| Contracts with activity | 78 |
| New contracts | 50 |
| Top agency | Department of Veterans Affairs |
| Top agency share | 85.1% |
|---|---|
| Agencies | 3 |
| Average remaining term | 3.2 months |
12 months through Jul 31, 2026
Largest New Awards
The 10 largest new awards total $30.17M, and the largest makes up 15.7% of that.
| Award ID | Agency | Recipient | Amount | Start | End | Description |
|---|---|---|---|---|---|---|
| 36C24826F0082 | Department of Veterans Affairs, Department of Veterans Affairs | NOVARTIS PHARMACEUTICALS CORPORATION | $4.73M | Feb 24, 2026 | Aug 31, 2026 | PLUVICTO |
| 36C25726N0205 | Department of Veterans Affairs, Department of Veterans Affairs | NOVARTIS PHARMACEUTICALS CORPORATION | $4.16M | Feb 7, 2026 | Feb 6, 2027 | LU177 - PLUVICTO/LUTATHERA |
| 36C26126F0007 | Department of Veterans Affairs, Department of Veterans Affairs | NOVARTIS PHARMACEUTICALS CORPORATION | $3.99M | Oct 1, 2025 | Sep 30, 2026 | PLUVICTO DRUG |
| 36C26226N0112 | Department of Veterans Affairs, Department of Veterans Affairs | NOVARTIS PHARMACEUTICALS CORPORATION | $3.91M | Nov 1, 2025 | Oct 31, 2026 | PLUVICTO AND LUTATHERA |
| W81K0025FA195 | Department of Defense, Department of the Army | NOVARTIS PHARMACEUTICALS CORPORATION | $3.23M | Oct 1, 2025 | Sep 30, 2026 | LUTATHERA AND PLUVICTO |
| 36C24926N0263 | Department of Veterans Affairs, Department of Veterans Affairs | ADVANCED ACCELERATOR APPLICATIONS USA INC | $2.91M | Dec 20, 2025 | Sep 30, 2026 | VISN PADIOPHARMACEUTICAL PLUVICTO DRUG |
| 36C25026N0310 | Department of Veterans Affairs, Department of Veterans Affairs | NOVARTIS PHARMACEUTICALS CORPORATION | $2.42M | Feb 1, 2026 | Dec 31, 2026 | RADIOPHARMACEUTICALS PLUVICTO / LUTATHERA |
| 36C24426F0063 | Department of Veterans Affairs, Department of Veterans Affairs | NOVARTIS PHARMACEUTICALS CORPORATION | $1.98M | Jan 1, 2026 | Dec 31, 2026 | RADIOPHARMACEUTICALS-LUTATHERA AND PLUVICTO INJECTIONS |
| 36C26126F0017 | Department of Veterans Affairs, Department of Veterans Affairs | NOVARTIS PHARMACEUTICALS CORPORATION | $1.63M | Oct 1, 2025 | Sep 30, 2026 | PLUVICTO FY26 |
| 36C25526N0132 | Department of Veterans Affairs, Department of Veterans Affairs | ADVANCED ACCELERATOR APPLICATIONS USA INC | $1.20M | Feb 17, 2026 | Feb 16, 2027 | PLUVICTO AND LUTATHERA |
Monthly Obligations
The latest complete month, Apr 2026, had net de-obligations of $1.12M. The largest month in the table was Oct 2024, at $17.99M.
| Month | Obligations |
|---|---|
| Jul 2026 | -$2.08M |
| Jun 2026 | -$1.01M |
| May 2026 | $360,010 |
| Apr 2026 | -$1.12M |
| Mar 2026 | -$998,364 |
| Feb 2026 | $12.22M |
| Jan 2026 | $2.02M |
| Dec 2025 | $10.85M |
| Nov 2025 | -$206,449 |
| Oct 2025 | $7.81M |
| Sep 2025 | $735,492 |
| Aug 2025 | $518,788 |
| Month | Obligations |
|---|---|
| Jul 2025 | -$1.71M |
| Jun 2025 | -$2.19M |
| May 2025 | -$1.04M |
| Apr 2025 | -$2.21M |
| Mar 2025 | -$1.95M |
| Feb 2025 | $4.61M |
| Jan 2025 | -$384,691 |
| Dec 2024 | $5.54M |
| Nov 2024 | $4.68M |
| Oct 2024 | $17.99M |
| Sep 2024 | -$4.44M |
| Aug 2024 | $1.59M |
Net obligations recorded each month, newest first. Agencies report contract actions with a delay (the Defense Department about 90 days), so the latest months, May to Jul 2026, are still incomplete and the 12-month total usually rises as agencies report the rest.
Frequently Asked Questions About NVS
How much does Novartis AG ADR receive in federal contracts?
Novartis AG ADR had $29.09M in federal contract obligations over the 12 months through Jul 31, 2026, compared with $20.49M in the 12 months before, up 42.0%. Obligations are contract bookings by the awarding agency, not recognized revenue.
What are Novartis AG ADR's largest government contracts?
The largest new awards over the 12 months through Jul 31, 2026 were 36C24826F0082, Department of Veterans Affairs, $4.73M, started Feb 24, 2026; 36C25726N0205, Department of Veterans Affairs, $4.16M, started Feb 7, 2026; 36C26126F0007, Department of Veterans Affairs, $3.99M, started Oct 1, 2025.
Which agencies award Novartis AG ADR contracts?
Department of Veterans Affairs was the top awarding agency with 85.1% of obligations over the 12 months through Jul 31, 2026. The records cover 3 agencies. Other agencies in the awards list include Department of Defense.
What new federal contracts did Novartis AG ADR win in the 12 months through Jul 31, 2026?
Novartis AG ADR won 50 new federal contracts in the 12 months through Jul 31, 2026. The largest was 36C24826F0082, Department of Veterans Affairs, $4.73M, started Feb 24, 2026.
How do Novartis AG ADR's federal obligations compare with its revenue?
Federal contract obligations were $29.09M over the 12 months through Jul 31, 2026, equivalent to less than 1% of Novartis AG ADR's revenue. Obligations are amounts the government committed to contracts in the period, not the share of Novartis AG ADR's revenue that comes from the government.
NVS pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts